Golden Biotechnology Corporation (TPEX:4132)

Market Cap	1.85B
Revenue (ttm)	40.92M
Net Income (ttm)	-360.70M
Shares Out	162.23M
EPS (ttm)	-2.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	480,183
Average Volume	386,336
Open	11.15
Previous Close	11.40
Day's Range	10.60 - 11.30
52-Week Range	10.60 - 22.25
Beta	0.85
RSI	29.05
Earnings Date	Aug 15, 2025

About Bally's

Golden Biotechnology Corporation operates as a drug discovery and healthy food supplement manufacturing company in Taiwan, the United States, Japan, China, Korea, and Singapore. Its products include Liverty that is used for liver health support and fatigue; Rasle, an auto-immune adjuvant therapy; ZSAINO, a nourishment product for recovery from illness and for health improvement; and UMOOZE, a herbal formula for optimal health in males. The company also provides Antroquinonol, an anticancer molecule for the treatment of pancreatic cancer, acute ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 122
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4132

Financial Performance

In 2024, Golden Biotechnology's revenue was 40.92 million, a decrease of -35.49% compared to the previous year's 63.43 million. Losses were -360.70 million, -0.26% less than in 2023.